Puromycin 2HCl structure
|
Common Name | Puromycin 2HCl | ||
---|---|---|---|---|
CAS Number | 58-58-2 | Molecular Weight | 544.43 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C22H31Cl2N7O5 | Melting Point | 168-170℃ | |
MSDS | Chinese USA | Flash Point | N/A | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of Puromycin 2HClPuromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis. |
Name | Puromycin dihydrochloride hydrate |
---|---|
Synonym | More Synonyms |
Description | Puromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis. |
---|---|
Related Catalog | |
In Vitro | Puromycin blocks protein synthesis after aminoacyl-sRNA formation, and at the same time it leads to the accumulation of small peptides. Both of these effects appear to be due to the splitting of ribosome-bound peptidyl-sRNA,4 which results in release of incomplete peptide chains.[1]. Puromycin, an analog of the 3' end of aminoacyl-tRNA, causes premature termination of translation by being linked non-specifically to growing polypeptide chains. Puromycin has two modes of inhibitory action. The first is by acting as an acceptor substrate which attacks peptidyl-tRNA in the P site to form a nascent peptide. The second is by competing with aminoacyl-tRNA for binding to the A' site[2]. When used in minimal amounts, puromycin incorporation in neosynthesized proteins reflects directly the rate of mRNA translation in vitro. Puromycin immunodetection is an advantageous alternative to radioactive amino acid labeling. It allows the direct evaluation of translation activity in single cells by immunofluorescence microscopy and in heterogenous populations of cells by fluorescenceactivated cell sorting[3]. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Melting Point | 168-170℃ |
Molecular Formula | C22H31Cl2N7O5 |
Molecular Weight | 544.43 |
PSA | 160.88000 |
LogP | 0.93 |
Index of Refraction | 1.701 |
Storage condition | −20°C |
Stability | Stable. Heat sensitive. Incompatible with strong oxidizing agents. |
Water Solubility | H2O: soluble50mg/mL (Sterilize stock solution by filtration using 0.22 μm filter then store in aliquots at 20 °C.) | Soluble in water |
Synonym: 3'- SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS
Risk Phrases: None Listed. SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW The toxicological properties of this material have not been fully investigated. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation.
Ingestion: May cause irritation of the digestive tract. Inhalation: May cause respiratory tract irritation. Chronic: Laboratory experiments have resulted in mutagenic effects. SECTION 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Skin: Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Ingestion: If victim is conscious and alert, give 2-4 cupfuls of milk or water. Never give anything by mouth to an unconscious person. Get medical aid immediately. Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Notes to Physician: SECTION 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Extinguishing Media: Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam. SECTION 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation. SECTION 7 - HANDLING and STORAGE Handling: Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Hormones and antibiotics room. SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 58-58-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use. SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: White Powder Odor: None reported. pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: Not available. Autoignition Temperature: Not available. Flash Point: Not available. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: Specific Gravity/Density: Molecular Formula: C22H29N7O5.2HCl.xH2O Molecular Weight: 544.44 SECTION 10 - STABILITY AND REACTIVITY Chemical Stability: Stable under normal temperatures and pressures. Conditions to Avoid: Incompatible materials, dust generation, strong oxidants. Incompatibilities with Other Materials: Strong oxidizing agents. Hazardous Decomposition Products: Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide, nitrogen. Hazardous Polymerization: Will not occur. SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 58-58-2: AU7355000 LD50/LC50: CAS# 58-58-2: Oral, mouse: LD50 = 720 mg/kg. Carcinogenicity: Puromycin dihydrochloride hydrate - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. SECTION 12 - ECOLOGICAL INFORMATION SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material. SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: Not available. Risk Phrases: Safety Phrases: S 24/25 Avoid contact with skin and eyes. S 28A After contact with skin, wash immediately with plenty of water. S 37 Wear suitable gloves. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 58-58-2: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 58-58-2 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 58-58-2 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION MSDS Creation Date: 12/12/1998 Revision #2 Date: 3/18/2003 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages. SECTION 16 - ADDITIONAL INFORMATION N/A |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 |
Personal Protective Equipment | Eyeshields;Faceshields;Gloves;half-mask respirator (US);multi-purpose combination respirator cartridge (US) |
Hazard Codes | Xn |
Risk Phrases | R22 |
Safety Phrases | S36 |
RIDADR | UN 3249 |
WGK Germany | 3 |
RTECS | AU7355000 |
Packaging Group | III |
Hazard Class | 6.1(b) |
Autophagy is involved in the initiation and progression of Graves' orbitopathy.
Thyroid 25(4) , 445-54, (2015) Differentiation of orbital fibroblasts into mature adipocytes and subsequent accumulation of adipose tissue has been shown in the progression of Graves' orbitopathy (GO). Autophagy is involved in adip... |
|
Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.
MAbs 6(6) , 1608-20, (2014) Anti-cytokine autoantibodies have been widely reported to be present in human plasma, both in healthy subjects and in patients with underlying autoimmune conditions, such as autoimmune polyendocrinopa... |
|
DEF6, a novel substrate for the Tec kinase ITK, contains a glutamine-rich aggregation-prone region and forms cytoplasmic granules that co-localize with P-bodies.
J. Biol. Chem. 287(37) , 31073-84, (2012) Localization of DEF6 (SLAT/IBP), a Rho-family guanine nucleotide exchange factor, to the center of the immune synapse is dependent upon ITK, a Tec-family kinase that regulates the spatiotemporal organ... |
PUROMYCIN |
EINECS 200-387-8 |
MFCD00067313 |
L-3'-(a-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine Dihydrochloride |
PUROMYCIN HYDROCHLORIDE |
Puromycin dihydrochloride |
Purine, 6-dimethylamino-9-[3-(p-methoxy-L-phenylalanylamino)-3-deoxy-.β.-D-ribofuranosyl]-, dihydrochloride |
L-3'-(a-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine |
(S)-3'-[[2-Amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyladenosine |
puromycinum [INN_la] |
6-Dimethylamino-9-[3-deoxy-3-(p-methoxy-L-phenylalanylamino)-b-D-ribofuranosyl]-b-purine |
Adenosine, 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl-, hydrochloride (1:2) |
P 638 dihydrochloride |
3'-{(E)-[(2S)-2-Amino-1-hydroxy-3-(4-methoxyphenyl)propylidene]amino}-3'-deoxy-N,N-dimethyladenosine |
3123-L |
3'-Deoxy-N,N-dimethyl-3'-[(O-methyl-L-tyrosyl)amino]adenosine dihydrochloride |
3'-(a-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine |
3'-(a-Amino-p-methoxyhydrocinnamamido)-3'-deoxy-N,N-dimethyladenosine Dihydrochloride |
Stylomycin dihydrochloride |
6-Dimethylamino-9-[3-deoxy-3-(p-methoxy-L-phenylalanylamino)-b-D-ribofuranosyl]-b-purine Dihydrochloride |
Stillomycin |
Adenosine, 3'-[[(1E,2S)-2-amino-1-hydroxy-3-(4-methoxyphenyl)propylidene]amino]-3'-deoxy-N,N-dimethyl- |
Adenosine, 3'-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3'-deoxy-N,N-dimethyl- |
3'-Deoxy-N,N-dimethyl-3'-[(O-methyl-L-tyrosyl)amino]adenosine |